![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PDGFRA |
Gene summary for PDGFRA |
![]() |
Gene information | Species | Human | Gene symbol | PDGFRA | Gene ID | 5156 |
Gene name | platelet derived growth factor receptor alpha | |
Gene Alias | CD140A | |
Cytomap | 4q12 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P16234 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5156 | PDGFRA | male-WTA | Human | Thyroid | PTC | 2.99e-03 | 4.90e-02 | 0.1037 |
5156 | PDGFRA | ATC12 | Human | Thyroid | ATC | 1.59e-67 | 1.44e+00 | 0.34 |
5156 | PDGFRA | ATC13 | Human | Thyroid | ATC | 1.03e-63 | 1.45e+00 | 0.34 |
5156 | PDGFRA | ATC3 | Human | Thyroid | ATC | 6.43e-04 | 3.19e-01 | 0.338 |
5156 | PDGFRA | ATC4 | Human | Thyroid | ATC | 1.30e-83 | 1.61e+00 | 0.34 |
5156 | PDGFRA | ATC5 | Human | Thyroid | ATC | 2.03e-80 | 1.53e+00 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
GO:0032956113 | Thyroid | PTC | regulation of actin cytoskeleton organization | 182/5968 | 358/18723 | 4.64e-14 | 2.79e-12 | 182 |
GO:0032970113 | Thyroid | PTC | regulation of actin filament-based process | 197/5968 | 397/18723 | 8.91e-14 | 4.89e-12 | 197 |
GO:0034599113 | Thyroid | PTC | cellular response to oxidative stress | 151/5968 | 288/18723 | 2.82e-13 | 1.43e-11 | 151 |
GO:0000302113 | Thyroid | PTC | response to reactive oxygen species | 121/5968 | 222/18723 | 2.10e-12 | 9.26e-11 | 121 |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:0042060112 | Thyroid | PTC | wound healing | 190/5968 | 422/18723 | 7.72e-09 | 1.92e-07 | 190 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:0034614112 | Thyroid | PTC | cellular response to reactive oxygen species | 82/5968 | 155/18723 | 4.32e-08 | 9.27e-07 | 82 |
GO:004677716 | Thyroid | PTC | protein autophosphorylation | 110/5968 | 227/18723 | 1.25e-07 | 2.44e-06 | 110 |
GO:003153220 | Thyroid | PTC | actin cytoskeleton reorganization | 60/5968 | 107/18723 | 1.91e-07 | 3.51e-06 | 60 |
GO:0033674111 | Thyroid | PTC | positive regulation of kinase activity | 201/5968 | 467/18723 | 1.95e-07 | 3.54e-06 | 201 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
GO:00480089 | Thyroid | PTC | platelet-derived growth factor receptor signaling pathway | 34/5968 | 56/18723 | 8.20e-06 | 9.42e-05 | 34 |
GO:0031032110 | Thyroid | PTC | actomyosin structure organization | 91/5968 | 196/18723 | 1.35e-05 | 1.45e-04 | 91 |
Page: 1 2 3 4 5 6 7 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Breast | ADJ |
PDGFB | PDGFRA | PDGFB_PDGFRA | PDGF | Breast | ADJ |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Breast | DCIS |
PDGFB | PDGFRA | PDGFB_PDGFRA | PDGF | Breast | DCIS |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Breast | Healthy |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Breast | IDC |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | Breast | IDC |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Cervix | ADJ |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Cervix | CC |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | Cervix | CC |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Cervix | Precancer |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | Cervix | Precancer |
PDGFB | PDGFRA | PDGFB_PDGFRA | PDGF | CRC | AD |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | CRC | AD |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | CRC | ADJ |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | CRC | CRC |
PDGFC | PDGFRA | PDGFC_PDGFRA | PDGF | CRC | CRC |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | CRC | MSS |
PDGFB | PDGFRA | PDGFB_PDGFRA | PDGF | CRC | MSS |
PDGFA | PDGFRA | PDGFA_PDGFRA | PDGF | Endometrium | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PDGFRA | SNV | Missense_Mutation | c.553G>T | p.Gly185Trp | p.G185W | P16234 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PDGFRA | SNV | Missense_Mutation | c.364C>A | p.Pro122Thr | p.P122T | P16234 | protein_coding | deleterious(0.02) | possibly_damaging(0.874) | TCGA-38-4632-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | gemcitabine | PD | |
PDGFRA | SNV | Missense_Mutation | novel | c.3096G>T | p.Glu1032Asp | p.E1032D | P16234 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-44-2668-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PDGFRA | SNV | Missense_Mutation | novel | c.659C>G | p.Ala220Gly | p.A220G | P16234 | protein_coding | deleterious(0) | benign(0.281) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
PDGFRA | SNV | Missense_Mutation | c.962N>A | p.Phe321Tyr | p.F321Y | P16234 | protein_coding | tolerated(0.2) | probably_damaging(0.98) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PDGFRA | SNV | Missense_Mutation | c.2762C>G | p.Ala921Gly | p.A921G | P16234 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-44-8119-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PDGFRA | SNV | Missense_Mutation | c.650N>T | p.Glu217Val | p.E217V | P16234 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-49-6767-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PDGFRA | SNV | Missense_Mutation | novel | c.213N>G | p.Ile71Met | p.I71M | P16234 | protein_coding | tolerated(0.28) | possibly_damaging(0.624) | TCGA-50-5066-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
PDGFRA | SNV | Missense_Mutation | c.1344N>T | p.Met448Ile | p.M448I | P16234 | protein_coding | tolerated(0.14) | benign(0.014) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
PDGFRA | SNV | Missense_Mutation | novel | c.2618N>A | p.Thr873Asn | p.T873N | P16234 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | IMATINIB | IMATINIB | 15928335,15685537,22718859,16638875,15146165,12949711,26130666,25157968,24132921,14645423,16954519,18794084,22745105 | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | DASATINIB | DASATINIB | 15928335,15685537,22718859,16638875,15146165,12949711,26130666,25157968,14645423,16954519,18794084,22745105 | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | VANDETANIB | VANDETANIB | ||
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | 363894199 | ||
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | CP-868596 | CRENOLANIB | ||
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | 249565576 | ENMD-2076 | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | LINIFANIB | LINIFANIB | ||
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | antibody | OLARATUMAB | OLARATUMAB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | inhibitor | 178102559 | NINTEDANIB | |
5156 | PDGFRA | TYROSINE KINASE, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUG RESISTANCE | CYC-116 | CYC-116 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |